FDA gives nod for AstraZeneca’s Imfinzi to treat endometrial cancer
The US Food and Drug Administration has approved AstraZeneca’s combination therapy, Imfinzi, for adult patients with endometrial cancer, according to a company statement.
Drugs
Health
Pharma
Drugs
Health
Pharma
US audit finds gaps in FDA’s procedures during infant formula crisis
The US drug regulator, FDA, did not have an organizational structure or assigned responsibilities to handle whistleblower complaints “efficiently and effectively” and took.
Drugs
Health
Pharma
AstraZeneca’s trial drug for mantle cell lymphoma raises survival rate
AstraZeneca’s mantle cell lymphoma combination rug, Calquence, reduced the risk of disease progression or death by up to 27%, according to a company.
Drugs
Health
Pharma
Pfizer’s blood cancer trial data shows survival of more than 2 years
Pfizer Inc.,’s investigational drug for blood cancer, Elrexfio, has shown an overall survival rate of 24.6 months in a single-arm trial, according to.
Drugs
Health
Pharma
Vaccine Alliance steps up bid to end rabies by 2030 after Covid-19 pause
The UN’s Gavi, the Vaccine Alliance, has restored its efforts to prevent and control rabies globally by increasing the availability of vaccines and.
Drugs
Health
Pharma
US healthcare costs cross GDP rate at $4.8 trillion in 2023
HQ Team June 14, 2025: The United States has the highest expenditure on health care per capita globally. It has risen 7.5% in.
Drugs
Medical
Pharma
Israel’s Teva Pharmaceuticals sue Corcept, Optime over drug monoploy
Israel’s Teva Pharmaceuticals has sued US-based Corcept Therapeutics and Optime Care Inc., a specialty pharma, for monopolising the market for a drug used to.
Drugs
Health
Pharma
Genetic factors may help predict loss of X chromosome in older women
Researchers co-led by the US-based National Cancer Institute have found genetic variants in women that may play a role in promoting abnormal blood.
Drugs
Health
Pharma
FDA approves AstraZeneca’s type-2 diabetes drug in US market
AstraZeneca’s oral drug to treat type-2 diabetes in patients aged 10 years and above has got approval from the US drug regulator, according.
Drugs
Health
Pharma
Pfizer’s Duchenne muscular dystrophy trial fails to meet primary goal
Pfizer’s investigations on gene therapy for patients with Duchenne muscular dystrophy failed to meet its primary goals, according to a company statement.